Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

are clearly making significant progress in executing on our dual-path business strategy," said Dr. Allan. "Both our FOBs and IPLEX(TM) programs achieved substantial milestones in 2007, and possess significant momentum as we move through 2008. We intend to initiate clinical trials for our first two FOBs this year and will continue to have an active voice on the regulatory pathway issue. In addition, we expect to continue moving IPLEX(TM) through the clinic in multiple indications, having prioritized MMD as the initial primary indication."

Financial Results for Fourth Quarter and Full-year 2007

Revenues for the fourth quarter ended December 31, 2007 were $2.1 million, up from $502,000 for the corresponding period in 2006. The increase was mainly attributable to improvements in cost recovery from our EAP to treat patients with ALS. This was partially offset by the revenues lost from our withdrawal of IPLEX(TM) from the short stature market pursuant to the terms of our Settlement Agreement.

The net loss for the fourth quarter of 2007 was $3.3 million or $0.03 per share, compared with a net loss of $21.4 million or $0.21 per share in the fourth quarter of 2006. This improvement was attributable to a reduction in selling, general and administrative expenses ("SG&A Expenses"), which fell to $947,000 from $9.7 million and the elimination of both a $7.1 million asset impairment charge and an $836,000 cost of goods sold charge, which occurred in 2006. These were partially offset by an increase in research and development expenses ("R&D Expenses") from $4.3 million to $4.5 million.

The reduction in SG&A Expenses was due primarily to reduced litigation expenses and the elimination of commercial expenses associated with our business restructuring plan. The elimination of the asset impairment charge and cost of goods sold resulted from our withdrawal of IPLEX(TM) from the short stature market, while the higher R&D Expenses reflected an increase in our
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 A new market research ... is available from Strategic Consulting, Inc., the leading ... Microbiology Market Review, Fourth Edition: Global Review of ... tracks and compares microbiology test volumes, market values ... and Asia, and forecasts future volumes and market ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/28/2014)... August 28, 2014 Whitehouse Laboratories is ... term partnership with PTI Inspection Systems that ... state of the art leak testing method development and ... instruments currently available. As part of this agreement, Whitehouse ... Voltage Leak Detection Instrument developed and manufactured by ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... YORK, Aug. 14 Summertime equals fun for ... irritable bowel syndrome (IBS), typical,summer fare could also ... author of "Recipes for IBS," has more on,what ... months to prevent IBS from,ruining their celebrations. ...
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... that develops, manufactures and markets advanced in-,vitro diagnostic ... today announced that it will participate in the ... Hong Kong Date: August 21, 2007 ...
... - YM BioSciences Inc.,(AMEX: YMI , ... that identifies,develops and commercializes differentiated products for ... Germany), its European partner,for the development of ... the 40th and final patient in its ...
Cached Biology Technology:ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 2ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 4
(Date:8/27/2014)... DURHAM, N.C. -- When we want to listen carefully ... talking. The second thing we do is stop moving ... unwanted sounds generated by our own movements. , This ... deep in the brain. Indeed, indirect evidence has long ... somehow influences the auditory cortex, which gives rise to ...
(Date:8/27/2014)... beasts. But every creature is a baby once. , ... of 24 very young dinosaurs and one older individual ... a caretaker, according to a new study by University ... Peter Dodson led the work, collaborating with researchers from ... is held. Hedrick is a doctoral student in the ...
(Date:8/27/2014)... doubt the long-standing belief that a deficiency in serotonin ... a central role in depression. In the journal ... the ability to make serotonin in their brains (and ... not show depression-like symptoms. , Donald Kuhn and ... and Wayne State University School of Medicine note that ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... AMES, Iowa When your family members gather at a picnic ... maybe more -- enjoying your barbecue. When flies visit your ... have more than 152,000 cousins. And those are just the ones ... of a team of scientists who have recently researched the fly ...
... think you see a face in the clouds or in the ... down. It turns out the answer to this seemingly minor ... Using tests of visual perception and functional magnetic resonance imaging (fMRI), ... Centre for Brain & Mind recently measured activity in two regions ...
... very familiar with land-use planning. But what is the ... and oceans? That question has gained importance since President ... charged it with developing an ecosystem-based stewardship policy for ... A team of natural and social scientists led ...
Cached Biology News:Too many relatives ruining your picnic? Be glad the flies don't invite their cousins 2How do you manage US oceans? Look at local successes 2How do you manage US oceans? Look at local successes 3
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... Endogens Screening Sets contain the ... develop five colorimetric sandwich ELISA plates ... in 100 l/well of cell culture ... and Detection Antibodies, Recombinant Standard (5 ...
... organic acid analysis standard is ... organic salts; molecular weights range ... standard is provided for use ... and the organic acid analysis ...
Biology Products: